TROY, Mich. -- Delphi Medical Systems, a subsidiary of Delphi Corp., signed an exclusive agreement with Alliance Medical, Incorporated, to distribute Delphi IVantage™ infusion pumps, accessories and disposables in the United States.

"This distribution agreement complements our earlier agreement with Fresenius Kabi in Europe and Asia Pacific, and other agreements in Central and South America, for the IVantage infusion pump - now totaling more than $100 million in bookings," said Christophe Sevrain, managing director, Delphi Medical Systems. "We are very pleased to work with Alliance's top-notch distribution team."

Delphi's IVantage will bear both the Delphi Medical Systems logo and the Alliance Medical logo. Miniature and accurate, the dual battery-operated and AC-powered portable pump is lightweight and small enough to be hand-held, making it ideal for use at home or at alternate sites.

The pump is designed so it can be easily clipped onto various accessories, such as IV poles and wheelchairs. It includes a shoulder strap and belt-clip for increased mobility and could play an important role in hospitals, where it could be utilized for mobile in-patient care.

"Distributing Delphi's IVantage fits nicely into our distribution portfolio and is very timely given the situation in this market," said Chief Operating Officer Garrett Brown, Alliance Medical, Inc. "IVantage is the most versatile ambulatory pump on the market today. With the cost advantage, ease of use and safety at the base of the technology, we know as a distributor that we will see great and rapid market penetration with this product. We, at Alliance Medical Inc. are dedicated to providing our customers with the best medical devices to serve patient needs. "Delphi Medical Systems also manufactures respiratory care devices, dialysis machines, vision-testing equipment, vital signs monitoring devices, in-vitro diagnostics, and other medical devices. Delphi Medical Systems focuses on supplying OEMs and distributors the latest product technology as well as integrated solutions in medical devices."

"The distribution agreement with Alliance Medical means our IVantage infusion pump will now be distributed throughout the most of the world, underlining our global reach," explained Sevrain.

About Delphi Medical Systems
Delphi Medical Systems is a world-class provider of technology, products, and product development and manufacturing for Dialysis, Infusion, Respiratory Care, Vital Signs Monitoring, In-vitro diagnostics, and Power Mobility. Its capabilities stem from Delphi's vast technology base, product development expertise and manufacturing excellence. For more information on Delphi Medical Systems, please visit its website at: http://www.delphimedical.com. For more information on Delphi and all of its subsidiaries, visit http://www.delphi.com/media.

For more information on Alliance Medical Inc., visit its website at http://www.alliancemedical.org.

FORWARD-LOOKING STATEMENT
This press release as well as other statements made by Delphi may contain forward-looking statements within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, that reflect, when made, the Company's current views with respect to current events and financial performance. Such forward-looking statements are and will be, as the case may be, subject to many risks, uncertainties and factors relating to the Company's operations and business environment which may cause the actual results of the Company to be materially different from any future results, express or implied, by such forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to, the following: the ability of the Company to continue as a going concern; the ability of the Company to operate pursuant to the terms of the debtor-in-possession (DIP) facility; the Company's ability to obtain court approval with respect to motions in the chapter 11 proceeding prosecuted by it from time to time; the ability of the Company to develop, prosecute, confirm and consummate one or more plans of reorganization with respect to the chapter 11 cases; risks associated with third parties seeking and obtaining court approval to terminate or shorten the exclusivity period for the Company to propose and confirm one or more plans of reorganization, for the appointment of a chapter 11 trustee or to convert the cases to chapter 7 cases; the Company's ability to maintain contracts that are critical to its operations; the potential adverse impact of the chapter 11 cases on the Company's liquidity or results of operations; the ability of the Company to fund and execute its business plan; the ability of the Company to attract, motivate and/or retain key executives and associates; and the ability of the Company to attract and retain customers. Other risk factors are listed from time to time in the Company's SEC reports, including, but not limited to the annual report on Form 10-K for the year ended December 31, 2004 and its most recent quarterly report on Form 10-Q and current reports on Form 8-K. Delphi disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Similarly, these and other factors, including the terms of any reorganization plan ultimately confirmed, can affect the value of the Company's various pre-petition liabilities, common stock and/or other equity securities. No assurance can be given as to what values, if any, will be ascribed in the bankruptcy proceedings to each of these constituencies. Accordingly, the Company urges that the appropriate caution be exercised with respect to existing and future investments in any of these liabilities and/or securities.